## Paolo Curatolo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9218080/publications.pdf

Version: 2024-02-01

318 papers 16,146 citations

62 h-index 25230 113 g-index

329 all docs 329 does citations

times ranked

329

14060 citing authors

#	Article	IF	CITATIONS
1	Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway. Epilepsy and Behavior, 2022, 131, 107713.	0.9	10
2	Evolution of electroencephalogram in infants with tuberous sclerosis complex and neurodevelopmental outcome: a prospective cohort study. Developmental Medicine and Child Neurology, 2022, 64, 495-501.	1.1	3
3	The epilepsy–autism spectrum disorder phenotype in the era of molecular genetics and precision therapy. Epilepsia, 2022, 63, 6-21.	2.6	22
4	Sleep disorders and neuropsychiatric disorders in a pediatric sample of tuberous sclerosis complex: a questionnaire-based study. Sleep Medicine, 2022, 89, 65-70.	0.8	5
5	Association of Early MRI Characteristics With Subsequent Epilepsy and Neurodevelopmental Outcomes in Children With Tuberous Sclerosis Complex. Neurology, 2022, 98, .	1.5	8
6	Down-regulation of the brain-specific cell-adhesion molecule contactin-3 in tuberous sclerosis complex during the early postnatal period. Journal of Neurodevelopmental Disorders, 2022, 14, 8.	1.5	4
7	Use of Nutritional Supplements Based on L-Theanine and Vitamin B6 in Children with Tourette Syndrome, with Anxiety Disorders: A Pilot Study. Nutrients, 2022, 14, 852.	1.7	5
8	Current role of surgery for tuberous sclerosis complexâ€associated epilepsy. Pediatric Investigation, 2022, 6, 16-22.	0.6	6
9	Questionnaire-based assessment of sleep disorders in an adult population of Tuberous Sclerosis Complex. Sleep Medicine, 2022, 92, 81-87.	0.8	1
10	Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy. Drugs, 2021, 81, 101-123.	4.9	35
11	Developmental and epileptic encephalopathies: what we do and do not know. Brain, 2021, 144, 32-43.	3.7	81
12	Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the <scp>EPISTOP</scp> Trial. Annals of Neurology, 2021, 89, 304-314.	2.8	137
13	The Impact of COVID-19 on the Adaptive Functioning, Behavioral Problems, and Repetitive Behaviors of Italian Children with Autism Spectrum Disorder: An Observational Study. Children, 2021, 8, 96.	0.6	26
14	Surgery for drugâ€resistant tuberous sclerosis complexâ€associated epilepsy: who, when, and what. Epileptic Disorders, 2021, 23, 53-73.	0.7	17
15	Neuroimaging and genetic characteristics of malformation of cortical development due to mTOR pathway dysregulation: clues for the epileptogenic lesions and indications for epilepsy surgery. Expert Review of Neurotherapeutics, 2021, 21, 1-13.	1.4	2
16	Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes. Epilepsia, 2021, 62, 1208-1219.	2.6	19
17	TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2021, 12, 630378.	1.1	10
18	Sex Differences in Autism Spectrum Disorder: Repetitive Behaviors and Adaptive Functioning. Children, 2021, 8, 325.	0.6	15

#	Article	IF	CITATIONS
19	COVID-19 and social responsiveness: A comparison between children with Sotos syndrome and autism. Psychiatry Research, 2021, 299, 113851.	1.7	5
20	Use of Nutraceutical Ingredient Combinations in the Management of Tension-Type Headaches with or without Sleep Disorders. Nutrients, 2021, 13, 1631.	1.7	5
21	TrASDition Training: An online parental training for transition-age youth with autism spectrum disorder. Psychiatry Research, 2021, 300, 113930.	1.7	1
22	MicroRNAâ€34a activation in tuberous sclerosis complex during early brain development may lead to impaired corticogenesis. Neuropathology and Applied Neurobiology, 2021, 47, 796-811.	1.8	5
23	Results of quantitative EEG analysis are associated with autism spectrum disorder and development abnormalities in infants with tuberous sclerosis complex. Biomedical Signal Processing and Control, 2021, 68, 102658.	3.5	7
24	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA). Orphanet Journal of Rare Diseases, 2021, 16, 301.	1,2	15
25	Pharmacotherapy for Seizures in Tuberous Sclerosis Complex. CNS Drugs, 2021, 35, 965-983.	2.7	7
26	Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry. Frontiers in Neurology, 2021, 12, 697467.	1.1	13
27	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	1.0	230
28	Reevaluation of Serum Arylesterase Activity in Neurodevelopmental Disorders. Antioxidants, 2021, 10, 164.	2.2	5
29	Adjunctive everolimus therapy for tuberous sclerosis complexâ€associated refractory seizures: Results from the postextension phase of EXISTâ€3. Epilepsia, 2021, 62, 3029-3041.	2.6	16
30	Editorial: Tuberous Sclerosis Complex – Diagnosis and Management. Frontiers in Neurology, 2021, 12, 755868.	1.1	1
31	Tuberous sclerosisâ€associated epilepsy and intellectual disability: what role does the mammalian target of rapamycin pathway play?. Developmental Medicine and Child Neurology, 2020, 62, 269-269.	1.1	2
32	Effects of oral administration of common antioxidant supplements on the energy metabolism of red blood cells. Attenuation of oxidative stress-induced changes in Rett syndrome erythrocytes by CoQ10. Molecular and Cellular Biochemistry, 2020, 463, 101-113.	1.4	14
33	Myelin Pathology Beyond White Matter in Tuberous Sclerosis Complex (TSC) Cortical Tubers. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1054-1064.	0.9	21
34	Early Onset Epilepsy Caused by Low-Grade Epilepsy-Associated Tumors and Focal Meningeal Involvement. Brain Sciences, 2020, 10, 752.	1.1	1
35	Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. Frontiers in Neurology, 2020, 11, 972.	1.1	27
36	Impaired Motor Timing in Tourette Syndrome: Results From a Case–Control Study in Children. Frontiers in Neurology, 2020, 11, 552701.	1.1	7

#	Article	IF	CITATIONS
37	POLG1-Related Epilepsy: Review of Diagnostic and Therapeutic Findings. Brain Sciences, 2020, 10, 768.	1.1	6
38	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. Journal of Neurodevelopmental Disorders, 2020, 12, 24.	1.5	16
39	Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study. Frontiers in Neurology, 2020, 11, 904.	1.1	20
40	Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?. Annals of Clinical and Translational Neurology, 2020, 7, 1371-1381.	1.7	23
41	Impact of Italian lockdown on Tourette's syndrome patients at the time of the <scp>COVID</scp> â€19 pandemic. Psychiatry and Clinical Neurosciences, 2020, 74, 610-612.	1.0	13
42	Auditory Mismatch Negativity in Youth Affected by Autism Spectrum Disorder With and Without Attenuated Psychosis Syndrome. Frontiers in Psychiatry, 2020, 11, 555340.	1.3	5
43	Clustering Analysis Supports the Detection of Biological Processes Related to Autism Spectrum Disorder. Genes, 2020, 11, 1476.	1.0	8
44	Prediction of Neurodevelopment in Infants With Tuberous Sclerosis Complex Using Early EEG Characteristics. Frontiers in Neurology, 2020, 11, 582891.	1.1	19
45	Autism and Epilepsy in Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2020, 11, 639.	1.1	36
46	Developmental and epileptic encephalopathy due to SZT2 genomic variants: Emerging features of a syndromic condition. Epilepsy and Behavior, 2020, 108, 107097.	0.9	14
47	TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: results of the EPISTOP study. Genetics in Medicine, 2020, 22, 1489-1497.	1.1	51
48	Sleep problems in attention-deficit/hyperactivity disorder and autism spectrum disorder: Sex differences and parental stress. Psychiatry Research, 2020, 291, 113099.	1.7	6
49	Event-Related Potentials in ADHD Associated With Tuberous Sclerosis Complex: A Possible Biomarker of Symptoms Severity?. Frontiers in Neurology, 2020, 11, 546.	1.1	8
50	Long-term use of mTORC1 inhibitors in tuberous sclerosis complex associated neurological aspects. Expert Opinion on Orphan Drugs, 2020, 8, 215-225.	0.5	1
51	Treatment of infantile spasms: why do we know so little?. Expert Review of Neurotherapeutics, 2020, 20, 551-566.	1.4	13
52	Vitamin D Deficiency and Autism Spectrum Disorder. Current Pharmaceutical Design, 2020, 26, 2460-2474.	0.9	26
53	Use of nutritional supplements based on melatonin, tryptophan and vitamin B6 (Melamil Tripto $\hat{A}^{@}$ ) in children with primary chronic headache, with or without sleep disorders: a pilot study. Minerva Pediatrica, 2020, 72, 30-36.	2.6	8
54	Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype. Frontiers in Neurology, 2020, 11, 603.	1.1	7

#	Article	IF	Citations
55	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. Frontiers in Neurology, 2019, 10, 821.	1.1	18
56	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. Frontiers in Neurology, 2019, 10, 705.	1.1	22
57	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. Frontiers in Neurology, 2019, 10, 1144.	1.1	11
58	The TOSCA Registry for Tuberous Sclerosisâ€"Lessons Learnt for Future Registry Development in Rare and Complex Diseases. Frontiers in Neurology, 2019, 10, 1182.	1.1	3
59	Children With Autism Spectrum Disorder and Their Mothers Share Abnormal Expression of Selected Endogenous Retroviruses Families and Cytokines. Frontiers in Immunology, 2019, 10, 2244.	2.2	32
60	Disruption of mTOR and MAPK pathways correlates with severity in idiopathic autism. Translational Psychiatry, 2019, 9, 50.	2.4	81
61	Comorbidity between ADHD and anxiety disorders across the lifespan. International Journal of Psychiatry in Clinical Practice, 2019, 23, 238-244.	1.2	73
62	Early Clinical Predictors of Autism Spectrum Disorder in Infants with Tuberous Sclerosis Complex: Results from the EPISTOP Study. Journal of Clinical Medicine, 2019, 8, 788.	1.0	42
63	Autistic symptoms in Greig cephalopolysyndactyly syndrome: a family case report. Journal of Medical Case Reports, 2019, 13, 100.	0.4	6
64	Autistic Symptoms in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 78.	1.3	86
65	Risk and Protective Environmental Factors Associated with Autism Spectrum Disorder: Evidence-Based Principles and Recommendations. Journal of Clinical Medicine, 2019, 8, 217.	1.0	71
66	Diagnostic Yield of a Targeted Next-Generation Sequencing Gene Panel for Pediatric-Onset Movement Disorders: A 3-Year Cohort Study. Frontiers in Genetics, 2019, 10, 1026.	1.1	33
67	A novel KCTD17 mutation is associated with childhood early-onset hyperkinetic movement disorder. Parkinsonism and Related Disorders, 2019, 61, 4-6.	1.1	22
68	Epilepsy in tuberous sclerosis complex: Findings from the <scp>TOSCA</scp> Study. Epilepsia Open, 2019, 4, 73-84.	1.3	125
69	Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrology Dialysis Transplantation, 2019, 34, 502-508.	0.4	55
70	First Results of the EPISTOP Study. , 2019, 50, .		0
71	ATP1A3 -related epileptic encephalopathy responding to ketogenic diet. Brain and Development, 2018, 40, 433-438.	0.6	23
72	mTOR dysregulation and tuberous sclerosis-related epilepsy. Expert Review of Neurotherapeutics, 2018, 18, 185-201.	1.4	68

#	Article	IF	CITATIONS
73	Childhood Rapid-Onset Ataxia: Expanding the Phenotypic Spectrum of ATP1A3 Mutations. Cerebellum, 2018, 17, 489-493.	1.4	24
74	The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity. Clinical Drug Investigation, 2018, 38, 1-8.	1.1	41
75	Potential for diagnosis versus therapy monitoring of attention deficit hyperactivity disorder: a new epigenetic biomarker interacting with both genotype and auto-immunity. European Child and Adolescent Psychiatry, 2018, 27, 241-252.	2.8	41
76	Everolimus for Retinal Astrocytic Hamartomas in Tuberous Sclerosis Complex. Ophthalmology Retina, 2018, 2, 257-260.	1.2	9
77	The Decrease in Human Endogenous Retrovirus-H Activity Runs in Parallel with Improvement in ADHD Symptoms in Patients Undergoing Methylphenidate Therapy. International Journal of Molecular Sciences, 2018, 19, 3286.	1.8	13
78	Everolimus for treatment-refractory seizures in TSC. Neurology: Clinical Practice, 2018, 8, 412-420.	0.8	85
79	Current concepts on epilepsy management in tuberous sclerosis complex. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 299-308.	0.7	35
80	The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure: the Journal of the British Epilepsy Association, 2018, 63, 17-25.	0.9	52
81	TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet Journal of Rare Diseases, 2018, 13, 157.	1.2	106
82	Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex – Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy. Frontiers in Pharmacology, 2018, 9, 964.	1.6	22
83	Autism Spectrum Disorder: Why Do We Know So Little?. Frontiers in Neurology, 2018, 9, 670.	1.1	22
84	Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PLoS ONE, 2018, 13, e0201005.	1.1	27
85	Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opinion on Drug Safety, 2018, 17, 1015-1028.	1.0	26
86	Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. European Journal of Paediatric Neurology, 2018, 22, 738-748.	0.7	151
87	Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. The Lancet Child and Adolescent Health, 2018, 2, 495-504.	2.7	77
88	The Relationship between Sleep Problems, Neurobiological Alterations, Core Symptoms of Autism Spectrum Disorder, and Psychiatric Comorbidities. Journal of Clinical Medicine, 2018, 7, 102.	1.0	98
89	Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. European Journal of Paediatric Neurology, 2018, 22, 1066-1073.	0.7	54
90	A clinical update on tuberous sclerosis complexâ€associated neuropsychiatric disorders (TAND). American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2018, 178, 309-320.	0.7	71

#	Article	IF	CITATIONS
91	Oxygen exchange and energy metabolism in erythrocytes of Rett syndrome and their relationships with respiratory alterations. Molecular and Cellular Biochemistry, 2017, 426, 205-213.	1.4	6
92	TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients. Orphanet Journal of Rare Diseases, 2017, 12, 2.	1.2	166
93	Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas. Pediatric Neurology, 2017, 68, 59-63.	1.0	15
94	Immediate and prolonged-release melatonin in children with neurodevelopmental disabilities. Author reply to Prof. Zisapel. European Journal of Paediatric Neurology, 2017, 21, 420-421.	0.7	3
95	Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain and Development, 2017, 39, 464-469.	0.6	97
96	Neurological soft signs, but not theory of mind and emotion recognition deficit distinguished children with ADHD from healthy control. Psychiatry Research, 2017, 256, 96-101.	1.7	8
97	Coding and small non-coding transcriptional landscape of tuberous sclerosis complex cortical tubers: implications for pathophysiology and treatment. Scientific Reports, 2017, 7, 8089.	1.6	47
98	Drug Treatments for Core Symptoms of Autism Spectrum Disorder: Unmet Needs and Future Directions. Journal of Pediatric Neurology, 2017, 15, 134-142.	0.0	3
99	Advances in Autism Spectrum Disorder. Journal of Pediatric Neurology, 2017, 15, 095-095.	0.0	0
100	New Perspectives in Autism Spectrum Disorder associated with Tuberous Sclerosis. Journal of Pediatric Neurology, 2017, 15, 123-128.	0.0	0
101	Current role of perampanel in pediatric epilepsy. Italian Journal of Pediatrics, 2017, 43, 51.	1.0	25
102	Advances in Understanding Autism Spectrum Disorder. Journal of Pediatric Neurology, 2017, 15, 096-098.	0.0	0
103	OPTICAL COHERENCE TOMOGRAPHY AND INFRARED IMAGES OF ASTROCYTIC HAMARTOMAS NOT REVEALED BY FUNDUSCOPY IN TUBEROUS SCLEROSIS COMPLEX. Retina, 2017, 37, 1383-1392.	1.0	12
104	The Relationship between Autism Spectrum Disorder and Tourette Syndrome in Childhood: An Overview of Shared Characteristics. Journal of Pediatric Neurology, 2017, 15, 115-122.	0.0	7
105	Effect of Modified-Release Methylphenidate on Cognition in Children with ADHD: Evidence from a Temporal Preparation Task. Timing and Time Perception, 2016, 4, 207-222.	0.4	3
106	Comorbidity of ADHD and High-functioning Autism. Journal of Psychiatric Practice, 2016, 22, 22-30.	0.3	16
107	Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor. Pediatric Blood and Cancer, 2016, 63, 719-722.	0.8	7
108	The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs, 2016, 76, 551-565.	4.9	66

#	Article	IF	Citations
109	Combined targeted treatment in early onset epilepsy associated with tuberous sclerosis. Epilepsy & Behavior Case Reports, 2016, 5, 13-16.	1.5	4
110	Epilepsy Associated with Incontinentia Pigmenti. Journal of Pediatric Epilepsy, 2016, 05, 089-096.	0.1	0
111	Epilepsy in Tuberous Sclerosis Complex. Journal of Pediatric Epilepsy, 2016, 05, 064-069.	0.1	1
112	White matter disruption is associated with persistent seizures in tuberous sclerosis complex. Epilepsy and Behavior, 2016, 60, 63-67.	0.9	21
113	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet, The, 2016, 388, 2153-2163.	6.3	554
114	Neurological soft signs are associated with attentional dysfunction in children with attention deficit hyperactivity disorder. Cognitive Neuropsychiatry, 2016, 21, 475-493.	0.7	12
115	Can biological components predict short-term evolution in Autism Spectrum Disorders? A proof-of-concept study. Italian Journal of Pediatrics, 2016, 42, 70.	1.0	1
116	Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC. European Journal of Paediatric Neurology, 2016, 20, 203-211.	0.7	49
117	Toward targeted treatments in tuberous sclerosis. Expert Opinion on Orphan Drugs, 2016, 4, 243-253.	0.5	1
118	Effectiveness of community-based treatment on clinical outcome in children with autism spectrum disorders: An Italian prospective study. Developmental Neurorehabilitation, 2016, 19, 1-9.	0.5	12
119	Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS ONE, 2016, 11, e0158476.	1.1	146
120	Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurology, The, 2015, 14, 733-745.	4.9	437
121	Reduction in retinal nerve fiber layer thickness in tuberous sclerosis complex. Child's Nervous System, 2015, 31, 857-861.	0.6	4
122	Paediatric use of melatonin (Author reply to D. J. Kennaway). European Journal of Paediatric Neurology, 2015, 19, 491-493.	0.7	8
123	Genotype/Phenotype Correlations in Tuberous Sclerosis Complex. Seminars in Pediatric Neurology, 2015, 22, 259-273.	1.0	96
124	Introduction. Seminars in Pediatric Neurology, 2015, 22, 205-206.	1.0	2
125	Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex. Seminars in Pediatric Neurology, 2015, 22, 282-294.	1.0	16
126	Current role of melatonin in pediatric neurology: Clinical recommendations. European Journal of Paediatric Neurology, 2015, 19, 122-133.	0.7	219

#	Article	IF	Citations
127	Promoting Shared Decision Making to strengthen outcome of young children with Autism Spectrum Disorders: The role of staff competence. Research in Developmental Disabilities, 2015, 38, 48-63.	1.2	19
128	Mechanistic Target of Rapamycin (mTOR) in Tuberous Sclerosis Complex-Associated Epilepsy. Pediatric Neurology, 2015, 52, 281-289.	1.0	117
129	Detection of auto-antibodies to DAT in the serum: Interactions with DAT genotype and psycho-stimulant therapy for ADHD. Journal of Neuroimmunology, 2015, 278, 212-222.	1.1	37
130	Refractory absence seizures: An Italian multicenter retrospective study. European Journal of Paediatric Neurology, 2015, 19, 660-664.	0.7	17
131	Long-term outcome of epilepsy in patients with Prader–Willi syndrome. Journal of Neurology, 2015, 262, 116-123.	1.8	10
132	Emotional Lability in Children and Adolescents Affected by Tourette Syndrome. Journal of Pediatric Neurology, 2015, 13, 105-109.	0.0	2
133	Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. CNS Drugs, 2015, 29, 865-877.	2.7	31
134	Role of ADHD symptoms as a contributing factor to obesity in patients with MC4R mutations. Medical Hypotheses, 2015, 84, 4-7.	0.8	9
135	Characterization of ANKRD11 mutations in humans and mice related to KBG syndrome. Human Genetics, 2015, 134, 181-190.	1.8	52
136	Tourette syndrome and comorbid ADHD: causes and consequences. European Journal of Pediatrics, 2015, 174, 279-288.	1.3	24
137	Synapses as Therapeutic Targets for Autism Spectrum Disorders: An International Symposium Held in Pavia on July 4th, 2014. Frontiers in Cellular Neuroscience, 2014, 8, 309.	1.8	9
138	Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncology, The, 2014, 15, 1513-1520.	5.1	152
139	Planning Deficit in Children With Neurofibromatosis Type 1. Journal of Child Neurology, 2014, 29, 1320-1326.	0.7	16
140	TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet Journal of Rare Diseases, 2014, 9, 182.	1.2	62
141	Tourette Syndrome and Comorbid Conditions. Journal of Child Neurology, 2014, 29, 1383-1389.	0.7	47
142	Timing and Clinical Characteristics of Topiramate-Induced Psychosis in a Patient With Epilepsy and Tuberous Sclerosis. Clinical Neuropharmacology, 2014, 37, 38-39.	0.2	5
143	Current Advances in Childhood Absence Epilepsy. Pediatric Neurology, 2014, 50, 205-212.	1.0	71
144	Epilepsy associated with autism and attention deficit hyperactivity disorder: Is there a genetic link?. Brain and Development, 2014, 36, 185-193.	0.6	67

#	Article	IF	CITATIONS
145	Motor cortical inhibition in ADHD: modulation of the transcranial magnetic stimulation-evoked N100 in a response control task. Journal of Neural Transmission, 2014, 121, 315-325.	1.4	29
146	Recommendations for early diagnosis and intervention in autism spectrum disorders: An Italian–Israeli consensus conference. European Journal of Paediatric Neurology, 2014, 18, 107-118.	0.7	24
147	Human endogenous retroviruses and ADHD. World Journal of Biological Psychiatry, 2014, 15, 499-504.	1.3	47
148	Use of the DISCERN tool for evaluating web searches in childhood epilepsy. Epilepsy and Behavior, 2014, 41, 119-121.	0.9	42
149	Reduction in Retinal Nerve Fiber Layer Thickness in Young Adults with Autism Spectrum Disorders. Journal of Autism and Developmental Disorders, 2014, 44, 873-882.	1.7	29
150	Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. Epilepsy Research, 2014, 108, 542-546.	0.8	18
151	Are caesarean sections, induced labor and oxytocin regulation linked to Autism Spectrum Disorders?. Medical Hypotheses, 2014, 82, 713-718.	0.8	36
152	Headache and attention deficit and hyperactivity disorder in children: Common condition with complex relation and disabling consequences. Epilepsy and Behavior, 2014, 32, 72-75.	0.9	31
153	Current role of rufinamide in the treatment of childhood epilepsy: Literature review and treatment guidelines. European Journal of Paediatric Neurology, 2014, 18, 685-690.	0.7	32
154	Reflex myoclonic epilepsy in infancy: a critical review. Epileptic Disorders, 2013, 15, 114-122.	0.7	14
155	Pharmacotherapy of autism spectrum disorders. Brain and Development, 2013, 35, 119-127.	0.6	49
156	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	1.0	1,185
157	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	1.0	693
158	Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. European Journal of Paediatric Neurology, 2013, 17, 348-352.	0.7	92
159	Tourette Syndrome and comorbid ADHD: Current pharmacological treatment options. European Journal of Paediatric Neurology, 2013, 17, 421-428.	0.7	64
160	Is mTOR inhibition a systemic treatment for tuberous sclerosis?. Italian Journal of Pediatrics, 2013, 39, 57.	1.0	46
161	Rufinamide for refractory focal seizures: An open-label, multicenter European study. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 33-36.	0.9	23
162	Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2013, 381, 125-132.	6.3	687

#	Article	IF	Citations
163	Epilepsy in patients with Cornelia de Lange syndrome: A clinical series. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 356-359.	0.9	23
164	Electroclinical Features and Long-Term Outcome of Cryptogenic Epilepsy in Children with Down Syndrome. Journal of Pediatrics, 2013, 163, 1754-1758.	0.9	25
165	Attention impairment in childhood absence epilepsy: An impulsivity problem?. Epilepsy and Behavior, 2013, 27, 337-341.	0.9	36
166	Lacosamide in pediatric and adult patients: Comparison of efficacy and safety. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 210-216.	0.9	60
167	mTOR inhibitors as a new therapeutic option for epilepsy. Expert Review of Neurotherapeutics, 2013, 13, 627-638.	1.4	43
168	Seizures Induced by Desloratadine, A Second-Generation Antihistamine: Clinical Observations. Neuropediatrics, 2013, 44, 222-224.	0.3	16
169	Impairment in Flexible Regulation of Speed and Accuracy in Children with ADHD. Journal of the International Neuropsychological Society, 2013, 19, 1016-1020.	1.2	6
170	Pancreatic Neuroendocrine Tumor in a Child with a Tuberous Sclerosis Complex 2 (TSC2) Mutation. Endocrine Practice, 2013, 19, e124-e128.	1.1	16
171	Attention-deficit hyperactivity disorder and binge eating disorder in a patient with 2q21.1–q22.2 deletion. Psychiatric Genetics, 2012, 22, 202-205.	0.6	8
172	mTOR Inhibitors in Tuberous Sclerosis Complex. Current Neuropharmacology, 2012, 10, 404-415.	1.4	106
173	Neuropsychiatric impairment in children with Continuous Spikes and Waves during slow Sleep: A longâ€ŧerm follow-up study. Epilepsy and Behavior, 2012, 25, 558-562.	0.9	8
174	Long term clinical course of Tourette syndrome. Brain and Development, 2012, 34, 667-673.	0.6	79
175	Attention and executive functions profile in childhood absence epilepsy. Brain and Development, 2012, 34, 812-817.	0.6	69
176	Two epileptic syndromes, one brain: Childhood absence epilepsy and benign childhood epilepsy with centrotemporal spikes. Seizure: the Journal of the British Epilepsy Association, 2012, 21, 70-74.	0.9	20
177	Management of epilepsy associated with tuberous sclerosis complex (TSC): Clinical recommendations. European Journal of Paediatric Neurology, 2012, 16, 582-586.	0.7	178
178	Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: The first Italian prospective study. Epilepsy Research, 2012, 102, 94-99.	0.8	14
179	HERVs Expression in Autism Spectrum Disorders. PLoS ONE, 2012, 7, e48831.	1.1	55
180	Cluster Analysis of Autistic Patients Based on Principal Pathogenetic Components. Autism Research, 2012, 5, 137-147.	2.1	54

#	Article	IF	CITATIONS
181	Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report. Child's Nervous System, 2012, 28, 939-941.	0.6	9
182	mTOR Inhibitors in Tuberous Sclerosis Complex. Current Neuropharmacology, 2012, 10, 404-415.	1.4	64
183	Urinary $\langle i \rangle p \langle  i \rangle$ -cresol is elevated in small children with severe autism spectrum disorder. Biomarkers, 2011, 16, 252-260.	0.9	115
184	Hypnic headache in children. Cephalalgia, 2011, 31, 1673-1676.	1.8	20
185	De novo mosaic ring chromosome 18 in a child with mental retardation, epilepsy and immunological problems. European Journal of Medical Genetics, 2011, 54, 329-332.	0.7	16
186	Long term outcome in children affected by absence epilepsy with onset before the age of three years. Epilepsy and Behavior, 2011, 20, 366-369.	0.9	22
187	Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy and Behavior, 2011, 22, 735-739.	0.9	120
188	Efficacy of Rufinamide in Drug-Resistant Epilepsy: A Meta-analysis. Pediatric Neurology, 2011, 44, 347-349.	1.0	19
189	Autism in tuberous sclerosis: are risk factors identifiable and preventable?. Future Neurology, 2011, 6, 451-454.	0.9	3
190	Family-based association study of ITGB3 in autism spectrum disorder and its endophenotypes. European Journal of Human Genetics, 2011, 19, 353-359.	1.4	45
191	ADHD and genetic syndromes. Brain and Development, 2011, 33, 456-461.	0.6	51
192	MTHFR C677T and A1298C polymorphisms and cerebral stroke in two twin gestations. Child's Nervous System, 2011, 27, 665-669.	0.6	7
193	The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. Child's Nervous System, 2011, 27, 1203-1210.	0.6	54
194	Lack of Infection with XMRV or Other MLV-Related Viruses in Blood, Post-Mortem Brains and Paternal Gametes of Autistic Individuals. PLoS ONE, 2011, 6, e16609.	1.1	16
195	Can we change the course of epilepsy in tuberous sclerosis complex?. Epilepsia, 2010, 51, 1330-1331.	2.6	3
196	Principal pathogenetic components and biological endophenotypes in autism spectrum disorders. Autism Research, 2010, 3, 237-252.	2.1	85
197	Preterm birth and neurodevelopmental outcome: a review. Child's Nervous System, 2010, 26, 1139-1149.	0.6	168
198	Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges. Child's Nervous System, 2010, 26, 1495-1504.	0.6	48

#	Article	IF	Citations
199	Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. European Journal of Paediatric Neurology, 2010, 14, 146-149.	0.7	176
200	Attention deficit hyperactivity disorder in children with epilepsy. Brain and Development, 2010, 32, 10-16.	0.6	104
201	Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome. Brain and Development, 2010, 32, 425-427.	0.6	15
202	The neurobiological basis of ADHD. Italian Journal of Pediatrics, 2010, 36, 79.	1.0	117
203	The relationship between sleep and epilepsy: the effect on cognitive functioning in children. Developmental Medicine and Child Neurology, 2010, 52, 805-810.	1.1	83
204	Intractable epilepsy in tuberous sclerosis: is the tuber removal not enough?. Developmental Medicine and Child Neurology, 2010, 52, 987-987.	1.1	11
205	Tubers, epileptogenic foci, and epileptogenic networks in tuberous sclerosis. Epilepsia, 2010, 51, 2357-2359.	2.6	3
206	Efficacy of intensive versus nonintensive physiotherapy in children with cerebral palsy: a meta-analysis. International Journal of Rehabilitation Research, 2010, 33, 165-171.	0.7	55
207	Education in Child Neurology: The Role of the International Child Neurology Association (ICNA). Journal of Child Neurology, 2010, 25, 1444-1449.	0.7	3
208	Autism Spectrum Disorders in Tuberous Sclerosis: Pathogenetic Pathways and Implications for Treatment. Journal of Child Neurology, 2010, 25, 873-880.	0.7	76
209	Late-Onset Epileptic Spasms in Children With Pallister-Killian Syndrome: A Report of Two New Cases and Review of the Electroclinical Aspects. Journal of Child Neurology, 2010, 25, 238-245.	0.7	12
210	Comorbidity of ADHD and Dyslexia. Developmental Neuropsychology, 2010, 35, 475-493.	1.0	197
211	Vagus Nerve Stimulation for Refractory Epilepsy in Tuberous Sclerosis. Pediatric Neurology, 2010, 43, 29-34.	1.0	49
212	Decreased serum arylesterase activity in autism spectrum disorders. Psychiatry Research, 2010, 180, 105-113.	1.7	33
213	Autism spectrum disorders associated with chromosomal abnormalities. Research in Autism Spectrum Disorders, 2010, 4, 319-327.	0.8	11
214	Rufinamide in children and adults with Lennox–Gastaut syndrome: First Italian multicenter experience. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 587-591.	0.9	52
215	Benign childhood epilepsy with centrotemporal spikes and the multicomponent model of attention: A matched control study. Epilepsy and Behavior, 2010, 19, 69-77.	0.9	44
216	Levetiracetam in Childhood Epilepsy. Paediatric Drugs, 2010, 12, 177-186.	1.3	50

#	Article	IF	Citations
217	Sleep Spindle Activity Is Correlated With Reading Abilities in Developmental Dyslexia. Sleep, 2009, 32, 1333-1340.	0.6	54
218	Slow EEG Amplitude Oscillations During NREM Sleep and Reading Disabilities in Children With Dyslexia. Developmental Neuropsychology, 2009, 34, 539-551.	1.0	25
219	MRI Appearance of Sturge-Weber Syndrome in Tuberous Sclerosis Complex: Is the Neural Crest the Culprit?. Journal of Child Neurology, 2009, 24, 263-266.	0.7	7
220	Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain and Development, 2009, 31, 104-113.	0.6	191
221	The neurobiology of attention deficit/hyperactivity disorder. European Journal of Paediatric Neurology, 2009, 13, 299-304.	0.7	102
222	Clinical features of psychogenic non-epileptic seizures in prepubertal and pubertal patients with idiopathic epilepsy. Neurological Sciences, 2009, 30, 319-323.	0.9	38
223	Syndromic autism: causes and pathogenetic pathways. World Journal of Pediatrics, 2009, 5, 169-176.	0.8	77
224	Chikungunya and the nervous system: what we do and do not know. Reviews in Medical Virology, 2009, 19, 121-129.	3.9	71
225	Zonisamide in children and young adults with refractory epilepsy: An open label, multicenter Italian study. Epilepsy Research, 2009, 83, 112-116.	0.8	25
226	Deletion 2p25.2: A cryptic chromosome abnormality in a patient with autism and mental retardation detected using aCGH. European Journal of Medical Genetics, 2009, 52, 67-70.	0.7	16
227	Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions. CNS Drugs, 2009, 23, 739-753.	2.7	20
228	Pharmacotherapy of idiopathic generalized epilepsies. Expert Opinion on Pharmacotherapy, 2009, 10, 5-17.	0.9	6
229	Attention-Deficit Hyperactivity Disorder (ADHD) and Tuberous Sclerosis Complex. Journal of Child Neurology, 2009, 24, 1282-1287.	0.7	45
230	Abnormal parieto-motor connectivity in Tuberous Sclerosis Complex. Epilepsy Research, 2009, 87, 102-105.	0.8	8
231	Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. European Neuropsychopharmacology, 2009, 19, 822-834.	0.3	47
232	Epilepsy and electroencephalographic anomalies in chromosome 2 aberrations. Epilepsy Research, 2008, 79, 63-70.	0.8	13
233	Levetiracetam in juvenile myoclonic epilepsy: longâ€term efficacy in newly diagnosed adolescents. Developmental Medicine and Child Neurology, 2008, 50, 29-32.	1,1	45
234	Levetiracetam in absence epilepsy. Developmental Medicine and Child Neurology, 2008, 50, 850-853.	1.1	51

#	Article	IF	Citations
235	Vigabatrin and epilepsy: Further lessons in early childhood. Epilepsia, 2008, 49, 177-178.	2.6	О
236	Autism and Metabolic Diseases. Journal of Child Neurology, 2008, 23, 307-314.	0.7	103
237	Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: Significant clinical improvement during tamoxifen treatment. Journal of Hepatology, 2008, 48, 1026-1029.	1.8	18
238	Neurologic Aspects of Microcephalic Osteodysplastic Primordial Dwarfism Type II. Pediatric Neurology, 2008, 38, 435-438.	1.0	8
239	Deletion 2q37: An Identifiable Clinical Syndrome With Mental Retardation and Autism. Journal of Child Neurology, 2008, 23, 802-806.	0.7	25
240	Infantile Spasms: Ã Neuro-ophthalmological Study. Developmental Medicine and Child Neurology, 2008, 23, 449-453.	1.1	5
241	Infantile Spasms and the CHARGE Association. Developmental Medicine and Child Neurology, 2008, 25, 367-369.	1.1	25
242	Tuberous sclerosis. Lancet, The, 2008, 372, 657-668.	6.3	967
243	Genetics and Molecular Biology of Tuberous Sclerosis Complex. Current Genomics, 2008, 9, 475-487.	0.7	107
244	Lack of association between MTHFR C677T and MTHFR A1298C genetic polymorphisms and mental retardation. Nutritional Neuroscience, 2008, 11, 241-242.	1.5	4
245	Management of epilepsy in tuberous sclerosis complex. Expert Review of Neurotherapeutics, 2008, 8, 457-467.	1.4	34
246	Lack of Evidence for Association Between D2S124 and D2S111 Polymorphisms of the SCN2A Gene and Idiopathic Generalized Epilepsy With Generalized Tonicâ€"Clonic Seizures. Journal of Child Neurology, 2007, 22, 907-910.	0.7	1
247	Preface. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, IX.	1.0	O
248	Anophthalmia-Waardenburg Syndrome With Expanding Phenotype: Does Neural Crest Play a Role?. Journal of Child Neurology, 2007, 22, 1252-1255.	0.7	6
249	Sleep Architecture and NREM Alterations in Children and Adolescents with Asperger Syndrome. Sleep, 2007, 30, 1577-1585.	0.6	92
250	Genetic Polymorphisms and Idiopathic Generalized Epilepsies. Pediatric Neurology, 2007, 37, 157-164.	1.0	43
251	Tuberous sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, 129-151.	1.0	45
252	Educational, cognitive, behavioral and language development issues. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, 611-625.	1.0	0

#	Article	IF	CITATIONS
253	Medical treatment in children with central nervous system malformations. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 87, 555-568.	1.0	O
254	Does cesarean section prevent mortality and cerebral ultrasound abnormalities in preterm newborns?. Journal of Maternal-Fetal and Neonatal Medicine, 2007, 20, 151-159.	0.7	7
255	Clinical, Morphological, and Biochemical Correlates of Head Circumference in Autism. Biological Psychiatry, 2007, 62, 1038-1047.	0.7	131
256	Association between D18S474 locus on chromosome 18q12 and idiopathic generalized epilepsy. Brain and Development, 2007, 29, 9-12.	0.6	5
257	Interstitial deletion of a proximal 3p: A clinically recognisable syndrome. Brain and Development, 2007, 29, 312-316.	0.6	12
258	Attention and executive functions profile in drug naive ADHD subtypes. Brain and Development, 2007, 29, 400-408.	0.6	144
259	Disentangling the effects of Tourette syndrome and attention deficit hyperactivity disorder on cognitive and behavioral phenotypes. Brain and Development, 2007, 29, 413-420.	0.6	69
260	Current role of vigabatrin in infantile spasms. European Journal of Paediatric Neurology, 2007, 11, 331-336.	0.7	48
261	Hypohidrosis During Topiramate Treatment:A Rare and Reversible Side Effect. Pediatric Neurology, 2006, 34, 392-394.	1.0	50
262	Current management for epilepsy in tuberous sclerosis complex. Current Opinion in Neurology, 2006, 19, 119-123.	1.8	47
263	Deletion of the Long Arm of Chromosome 6: Report on a New Case With Intractable Epilepsy. Journal of Child Neurology, 2006, 21, 527-531.	0.7	2
264	Tuberous sclerosis complex and hydrosyringomielia: Report of two cases. European Journal of Paediatric Neurology, 2006, 10, 37-40.	0.7	1
265	Association of Adenosine Deaminase Polymorphism With Mild Mental Retardation. Journal of Child Neurology, 2006, 21, 753-756.	0.7	5
266	Tuberous sclerosis: genes, brain, and behaviour. Developmental Medicine and Child Neurology, 2006, 48, 404-404.	1.1	1
267	Tuberous sclerosis: genes, brain, and behaviour. Developmental Medicine and Child Neurology, 2006, 48, 404.	1.1	7
268	Title is missing!. European Journal of Paediatric Neurology, 2005, 9, 45.	0.7	0
269	Exanthematic diseases during pregnancy and attention-deficit/hyperactivity disorder (ADHD). European Journal of Paediatric Neurology, 2005, 9, 363-365.	0.7	18
270	The neurology of attention deficit/hyperactivity disorder. Brain and Development, 2005, 27, 541-543.	0.6	16

#	Article	IF	CITATIONS
271	Topical Review: Intractable Seizures in Tuberous Sclerosis Complex: From Molecular Pathogenesis to the Rationale for Treatment. Journal of Child Neurology, 2005, 20, 318-325.	0.7	82
272	Lack of association between IDE genetic variability and Down's syndrome. Neuroscience Letters, 2005, 382, 93-95.	1.0	1
273	Brain damage in preterm infants: etiological pathways. Annali Dell'Istituto Superiore Di Sanita, 2005, 41, 229-37.	0.2	28
274	Topical Review: Intractable Seizures in Tuberous Sclerosis Complex: From Molecular Pathogenesis to the Rationale for Treatment. Journal of Child Neurology, 2004, 19, 318-325.	0.7	0
275	Increased Brain Apparent Diffusion Coefficient in Tuberous Sclerosis. Radiology, 2004, 232, 461-465.	3 <b>.</b> 6	58
276	Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy. Neurology, 2004, 63, 373-375.	1.5	60
277	Autism in tuberous sclerosis. European Journal of Paediatric Neurology, 2004, 8, 327-332.	0.7	113
278	Epilepsy surgery for tuberous sclerosis. Pediatric Neurology, 2004, 31, 239-247.	1.0	62
279	Association between presenilin-1 â^'48C/T polymorphism and Down's syndrome. Neuroscience Letters, 2004, 367, 88-91.	1.0	7
280	Child neurology: role of the International Association. Developmental Medicine and Child Neurology, 2004, 46, 147-147.	1.1	2
281	Child neurology: role of the International Association. Developmental Medicine and Child Neurology, 2004, 46, 147.	1.1	1
282	Pharmacologic treatment of autism. Journal of Child Neurology, 2004, 19, 155-64.	0.7	30
283	A neurocutaneous disorder with a severe course: Wyburn-Mason's syndrome. Journal of Child Neurology, 2004, 19, 908-11.	0.7	8
284	Association study of autistic disorder and chromosome 16p. American Journal of Medical Genetics Part A, 2003, 119A, 242-246.	2.4	10
285	The role of â^3850 tumor necrosis factor-α and apolipoprotein E genetic polymorphism in patients with Down's syndrome-related dementia. Neuroscience Letters, 2003, 352, 29-32.	1.0	10
286	Neurologic Aspects of 49,XXXXY Syndrome. Journal of Child Neurology, 2003, 18, 501-504.	0.7	20
287	The International Child Neurology Association: Personal View. Journal of Child Neurology, 2003, 18, 786-794.	0.7	10
288	Convulsive disorder and the genetics of signal transduction; a study of a low molecular weight protein tyrosine phosphatase in a pediatric sample. Neuroscience Letters, 2002, 333, 159-162.	1.0	5

#	Article	IF	CITATIONS
289	Tuberous sclerosis complex: a review of neurological aspects. European Journal of Paediatric Neurology, 2002, 6, 15-23.	0.7	186
290	Two-loci ADA haplotypes in autistic disorder. American Journal of Medical Genetics Part A, 2002, 108, 339-340.	2.4	10
291	Vigabatrin for tuberous sclerosis complex. Brain and Development, 2001, 23, 649-653.	0.6	69
292	Infantile spasms in tuberous sclerosis complex. Brain and Development, 2001, 23, 502-507.	0.6	103
293	Autism: evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics, 2001, 3, 111-113.	0.7	62
294	Topical Review: Neurologic Aspects of Adenylosuccinate Lyase Deficiency. Journal of Child Neurology, 2001, 16, 301-308.	0.7	43
295	Prenatal and Perinatal Determinants of Neonatal Seizures Occurring in the First Week of Life. Journal of Child Neurology, 2001, 16, 651-656.	0.7	36
296	Neurologic Aspects of Adenylosuccinate Lyase Deficiency. Journal of Child Neurology, 2001, 16, 301.	0.7	30
297	Diffuse Polymicrogyria Associated With Congenital Hydrocephalus, Craniosynostosis, Severe Mental Retardation, and Minor Facial and Genital Anomalies. Journal of Child Neurology, 2000, 15, 493-495.	0.7	5
298	Differing Risk Factors for Cerebral Palsy in the Presence of Mental Retardation and Epilepsy. Journal of Child Neurology, 1999, 14, 151-155.	0.7	14
299	Seizures in Chiari I Malformation: A Clinical and Electroencephalographic Study. Journal of Child Neurology, 1999, 14, 446-450.	0.7	28
300	Sleep abnormalities in mentally retarded autistic subjects: Down's syndrome with mental retardation and normal subjects. Brain and Development, 1999, 21, 548-553.	0.6	115
301	Autism in tuberous sclerosis: evoked potential evidence for a deficit in auditory sensory processing. Clinical Neurophysiology, 1999, 110, 1825-1830.	0.7	118
302	Decrease in cerebral palsy mortality among children and adolescents in Italy from 1979 to 1993. Developmental Medicine and Child Neurology, 1999, 41, 67-67.	1,1	0
303	Magnetic source imaging and reactivity to rhythmical stimulation in tuberous sclerosis. Brain and Development, 1998, 20, 512-518.	0.6	24
304	Changes in cerebral blood flow velocities during childhood absence seizures. Pediatric Neurology, 1998, 18, 132-135.	1.0	32
305	Frontal Lobe Epilepsy Associated With Tuberous Sclerosis: Electroencephalographic-Magnetic Resonance Image Fusioning. Journal of Child Neurology, 1998, 13, 33-38.	0.7	34
306	Localization of seizure onset in epilepsy associated with Tuberous Sclerosis. Results of an EEG-MRI fusioning procedure. Neurolmage, 1996, 3, S514.	2.1	0

#	Article	IF	CITATIONS
307	Neurological manifestations of tuberous sclerosis complex. Child's Nervous System, 1996, 12, 515-21.	0.6	43
308	Sleep disorders in tuberous sclerosis: a polysomnographic study. Brain and Development, 1995, 17, 52-56.	0.6	71
309	RISK FACTORS FOR THE COOCCURRENCE OF PARTIAL EPILEPSY, CEREBRAL PALSY AND MENTAL RETARDATION. Developmental Medicine and Child Neurology, 1995, 37, 776-782.	1.1	24
310	Neuromagnetic 3D localization of interictal epileptogenic foci. Pediatric Neurology, 1994, 11, 131.	1.0	0
311	Vigabatrin in refractory partial seizures due to tuberous sclerosis. Pediatric Neurology, 1994, 11, 150-151.	1.0	0
312	Toxocara Infection and Epilepsy in Children: A Caseâ€Control Study. Epilepsia, 1990, 31, 33-36.	2.6	100
313	Polymicrogyria: A case detected by MRI. Brain and Development, 1989, 11, 257-259.	0.6	3
314	BAEPs in infantile spasms. Brain and Development, 1989, 11, 347-348.	0.6	4
315	Symmetrical bithalamic hyperdensities in asphyxiated full-term newborns: An early indicator of status marmoratus. Brain and Development, 1988, 10, 57-59.	0.6	8
316	Autism and Infantile Spasms in Children with Tuberous Sclerosis. Developmental Medicine and Child Neurology, 1987, 29, 551-551.	1,1	25
317	Tuberous Sclerosis: Diagnostic and Prognostic Problems. Pediatric Neurosurgery, 1985, 12, 123-125.	0.4	13
318	Gelastic Epilepsy and True Precocious Puberty due to Hypothalamic Hamartoma. Developmental Medicine and Child Neurology, 1984, 26, 509-514.	1.1	30